1737

To determine the association between the levels of urinary 15-F2t-isoprostane (15-F2t-IsoP), a marker of oxidative damage, and risk of hepatocellular carcinoma (HCC), a case-control study nested within a community based cohort was conducted in Taiwan. Baseline urine samples, collected from a total of 74 HCC cases and 290 matched controls, were used to determine the level of urinary 15-F2t-IsoP by competitive enzyme-linked immunosorbent assay. Conditional logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI) to assess the effect of urinary 15-F2t-IsoP on risk of HCC. The geometric mean of urinary 15-F2t-IsoP was 9.39 pmol/ml in HCC cases and 6.80 pmol/ml in controls. When compared to subjects in the lowest quartile, there was a trend in increasing (ptrend=0.03) risk of HCC with increasing quartiles of 15-F2t-IsoP level (OR=1.70, 95% CI=0.67-4.32, OR=1.88, 95% CI=0.73-4.84, OR=2.81, 95% CI=1.11-7.11 for the 2nd, 3rd and 4th quartile relative to the lowest quartile, respectively). In addition, the combination of urinary 15-F2t-IsoP above the mean and chronic hepatitis B virus infection (CHB) resulted in an OR of 15.17 (95%CI=5.66-40.71), compared to those with low urinary 15-F2t-IsoP and without CHB. These results demonstrate that elevated urinary levels of 15-F2t-IsoP is associated with an increased risk of HCC and that CHB may modify the role of urinary excretion of 15-F2t-IsoP in HCC risk.

98th AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA